Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?
A partir d'une revue systématique de la littérature (35 études, 953 patients), cette méta-analyse évalue l'efficacité, du point de vue du nombre de patients obtenant une rémission complète, de différents types d'immunothérapies à base de lymphocytes CAR-T ciblant CD19 chez des patients atteints d'une leucémie lymphoïde aiguë réfractaire ou récidivante
In the past decade, chimeric antigen receptor (CAR) T cells have revolutionised the treatment of relapsed B-cell acute lymphocytic leukaemia. 5 years after the first use in treatment of a child with B-cell acute lymphocytic leukaemia, 1 tisagenlecleucel received regulatory approval for the treatment of relapsed and refractory B-cell acute lymphocytic leukaemia in patients aged 25 years or younger, and this approval now extends across multiple jurisdictions. Furthermore, a wide range of CAR T cells are now under investigation for the treatment of B-cell acute lymphocytic leukaemia in addition to a multitude of other cancers.
The Lancet Haematology , commentaire, 2019